EUVIMEDEUVIMED entdecken
Open Access

Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer–Associated Germline Pathogenic Variants in Mexico

Fernanda Mesa-Chavez iD, Yanin Chavarri-Guerra iD, Dione Aguilar-Y-Mendez iD, Andrea Becerril-Gaitan iD, Bryan F Vaca-Cartagena iD, Araceli Carrillo-Bedoya, Salvador Santiesteban-González, Alejandro Aranda-Gutierrez iD, Andrés Rodríguez-Faure, Daniela Obregon-Leal, Gregorio Quintero-Beuló iD, Jose L Rodriguez-Olivares iD und 3 weitere

JCO Global Oncology · 2024

DOI: 10.1200/go.23.00417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Fernanda Mesa-Chavez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Genetic cancer risk assessment (GCRA) provides pathogenic variant (PV) carriers with the invaluable opportunity to undertake timely cancer risk-reducing (RR) measures and initiate cascade testing (CT). This study describes the uptake of these strategies and the related barriers among breast cancer–associated germline PV carriers in Mexico. METHODS Carriers who were at least 6 months after disclosure of genetic test results at two GCRA referral centers were invited to answer a survey assessing sociodemographic characteristics, awareness of their carrier status and its implications, uptake of RR measures according to international guidelines by PV, CT initiation, and associated challenges. RESULTS Of the eligible carriers, 246/384 (64%) answered the survey (median age: 44 years). Most were female (88%), married/in domestic partnership (66%), and had personal breast/ovarian cancer history (61%). PVs included BRCA1/ 2 (75%), CHEK2 (10%), PALB2 (5%), ATM (5%), NF1 (2%), RAD51C (2%), PTEN (1%), and TP53 (1%). Most (87%) participants were aware of their carrier status. When recommended, 37% underwent RR bilateral mastectomy, 48% RR oophorectomy, 70% annual mammogram, and 20% breast magnetic resonance imaging. Challenges hindering the uptake of RR measures included financial limitations (67%), lack of recommendation by their physician (35%), and fear (24%). Nearly all (98%) claimed sharing their results with their relatives. CT was initiated in 63% of families and was associated with carriers being married/in domestic partnership ( P = .04) and believing GCRA was useful ( P < .001). CONCLUSION Despite the resource-constrained setting, relevant rates of RR measures and CT were observed. Targeted interventions to reduce out-of-pocket expenses and improve patient-physician communication and patients' understanding on carrier status are warranted to enhance the overall benefit of GCRA and ultimately improve the provision of patient-centered care to both carriers and their at-risk relatives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleAdultBRCA1 ProteinMexicoGenetic Predisposition to DiseaseBRCA2 ProteinMastectomyGerm Cells

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico.
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, Monterrey, Mexico.
  • The University of Kansas Cancer Center, Kansas City, MO.
  • Latin American School of Oncology, Sierra Madre, CA.

ORCID-Profile: Fernanda Mesa-Chavez, Yanin Chavarri-Guerra, Dione Aguilar-Y-Mendez, Andrea Becerril-Gaitan, Bryan F Vaca-Cartagena, Alejandro Aranda-Gutierrez, Gregorio Quintero-Beuló, Jose L Rodriguez-Olivares, Melina Miaja, Jeffrey N Weitzel, Cynthia Villarreal-Garza

Förderung

  • NCI NIH HHS

Zitieren

APA

Mesa-Chavez, F., Chavarri-Guerra, Y., Aguilar-Y-Mendez, D., Becerril-Gaitan, A., Vaca-Cartagena, B. F., Carrillo-Bedoya, A., Santiesteban-González, S., Aranda-Gutierrez, A., Rodríguez-Faure, A., Obregon-Leal, D., Quintero-Beuló, G., Rodriguez-Olivares, J. L., Miaja, M., Weitzel, J. N., & Villarreal-Garza, C. (2024). Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer–Associated Germline Pathogenic Variants in Mexico. JCO Global Oncology. https://doi.org/10.1200/go.23.00417

Vancouver

Mesa-Chavez F, Chavarri-Guerra Y, Aguilar-Y-Mendez D, Becerril-Gaitan A, Vaca-Cartagena BF, Carrillo-Bedoya A, et al. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer–Associated Germline Pathogenic Variants in Mexico. JCO Global Oncology. 2024. doi:10.1200/go.23.00417

BibTeX
@article{MesaChavez2024,
  author = {Mesa-Chavez, Fernanda and Chavarri-Guerra, Yanin and Aguilar-Y-Mendez, Dione and Becerril-Gaitan, Andrea and Vaca-Cartagena, Bryan F and Carrillo-Bedoya, Araceli and Santiesteban-González, Salvador and Aranda-Gutierrez, Alejandro and Rodríguez-Faure, Andrés and Obregon-Leal, Daniela and Quintero-Beuló, Gregorio and Rodriguez-Olivares, Jose L and Miaja, Melina and Weitzel, Jeffrey N and Villarreal-Garza, Cynthia},
  title = {Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer–Associated Germline Pathogenic Variants in Mexico},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.23.00417}
}
Kostenlos starten →